ABF Ingredients (ABFI) has acquired Fytexia Group, a life science company developing scientifically supported active nutrients for dietary supplements. This strategic acquisition will expand ABFI’s portfolio of products and capabilities to better serve the pharmaceutical, nutritional and food market sectors.

Headquartered in France, with a strong presence in Europe and regional offices in the US and Asia, Fytexia Group is ideally positioned to serve customers globally. Fytexia Group focuses on the research and scientific validation of bioactive compounds to deliver functional ingredients for the improvement of human health and wellbeing, targeting non-communicable diseases. Fytexia Group is comprised of two businesses, Fytexia, a global expert in polyphenols, and B Natural, the European leader for the extraction and refinement of brown propolis.

“Fytexia Group is a strong science driven business with a successful track record servicing the dietary supplements industry. Fytexia Group will make an excellent addition to our family of businesses by bringing expertise in polyphenols and health and nutrition active ingredients extracts from botanicals and propolis, therefore strengthening the ABFI offering in health and nutrition ingredients,” said Fabienne Saadane-Oaks, CEO of ABFI.

“We are very excited to join ABFI. We share the same values and are both convinced that natural science based nutritional solutions are the future of the industry,” added said Matthieu Arguillère, CEO of Fytexia Group. “At Fytexia Group, we believe ABFI is the perfect partner to accelerate the development of our activity globally in the best possible conditions, with the support of a larger organization. Therefore, we will accelerate our clinical research to support our existing product line as well as our future developments.”

Robin Filmer-Wilson is a partner for Fytexia Group’s majority owner ArchiMed.

“Fytexia Group has demonstrated over the last few years an outstanding track record of growth, driven by strong investments in science and product development, and international expansion, under the majority ownership of ArchiMed,” said Filmer-Wilson. “The company is now a recognized category leader in polyphenols, which are a strategic class of molecules for nutraceuticals, with proven metabolic and physiological properties and increasing scientific traction. It has been a real pleasure working closely with Matthieu Arguillère and his team to accelerate the development of Fytexia Group through a buy-and-build strategy. We have been convinced by the strategic plan shared between ABFI and the management team and we wish them a great success for this new venture.”

About ABF Ingredients
ABFI, a division of Associated British Foods plc, is a specialty ingredients world leader which offers innovative, differentiated, and value-added products and services to the food, nutrition, pharmaceutical, animal feed and industrial sectors.

 ABFI comprises a group of companies operating worldwide under their own identities:

•             AB Enzymes – enzymes
•             ABITEC Corporation – specialty lipids and surfactants
•             Ohly – yeast extracts and culinary powders
•             PGP International – extruded ingredients and specialty flours
•             SPI Pharma – antacids, pharmaceutical excipients, and drug development services

www.abfingredients.com/en

About Fytexia Group
Fytexia Group’s mission is to reduce risk factors for non-communicable diseases by offering innovative nutritional ingredients developed through science-based research. Fytexia Group’s team of experts and its global network of researchers deliver functional active nutrients, developed through the application of stringent scientific principles and practices. The company’s activities range from the development of active compounds to the creation of clinically tested ingredients. The ingredients developed by Fytexia Group are used in the formulas of the most advanced healthcare products, improving the health and well-being of consumers worldwide.